{"name":"Afimmune","slug":"afimmune","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPT0RPUTl5cHVKb2dyb2hfU2JZcXJpbUxlejNIbXRsc2JIMm1pNndYZDRNOHdROVdiV2t0Q3l4MkJRVFdYREhaTXhIZF9pRnBqeFJuLTlaNnp0bHVRUHlOSHc5bEVIM2szdlhaQS1vUE4wVFhJU0lBejdCeHVGNFhGZVpYc0x0UXJ2TzZwUUlqQUNkR2tVM1hPWDRacG5UWHlYTTJrU194b3JMaUR0VUJsYTBEY3NSbjRCUUVSSmpvYUc3MVNYRC1kcUNGU1g0cW12RkNyNW9TZUFkUGxjLXdzZ1QtaGhBanlkTFFv?oc=5","date":"2021-08-26","type":"trial","source":"businesswire.com","summary":"Afimmune's Epeleuton shows large decreases in viral load and pathological changes in COVID-19 study - businesswire.com","headline":"Afimmune's Epeleuton shows large decreases in viral load and pathological changes in COVID-19 study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNNVpNSERzQk9kQnB5RzJTLUxPZ2xCTjZmd2JoTGhaei1YaTJyZjJfbHN6OVZMQkR3cHllSFpqV19aS1ZZVzZpTlQyQ3VBejVOTEtJZTE5N1FmcGxfMUducHpUcWhKUjNaSnhvOWtwUzVIZEdXQ0hIQ281VDU5azdEOEdrTVcwLXB2Tnlhdk1DMFJkbHJDdTdTR1h3eENYaTZ6WFRoYVVmUjZYd05wQ0VTaEs5RXlFUQ?oc=5","date":"2021-02-28","type":"pipeline","source":"The Times","summary":"How scientists John Climax and Dr Ronan Lambe created an Icon - The Times","headline":"How scientists John Climax and Dr Ronan Lambe created an Icon","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE11OTBST19ESFYwZnNzQ3pLcVVlOTFSUGJLYzhXcXh4a191Mk9RT3U5c080amU4WEc3UGdkYTgtUHlwTUt3TEpiNXNNX3R3MWtfRlMwM3VDWTNGTFBGV1ZKRUF0a3ZlZk1lZTUwVktR?oc=5","date":"2016-08-23","type":"pipeline","source":"pharmaphorum","summary":"DS Biopharma launches liver drug spin-out - pharmaphorum","headline":"DS Biopharma launches liver drug spin-out","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQOGdzWmdyVER4a2NaWTh4VHdrZGNOR3poN2JmZFlxQW1zeDQ4SHdvVGdpS3NTNm5HcGYyZXF0SVE5aU9La0VvZU5oeVNGSzRraHROMmtVM2JNbjVrcm0xVTh1REpLdUtMalB6UmM2SVYtdjVWSzRzRXp4VVloWXhJZnA3RFRUSnktbkQxYjVxTkpKc2xBMVFmVDlxV0FYZTQ4NTNqbA?oc=5","date":"2016-08-22","type":"pipeline","source":"Fierce Biotech","summary":"DS Biopharma spins out biotech to focus on NASH, fibrotic candidates - Fierce Biotech","headline":"DS Biopharma spins out biotech to focus on NASH, fibrotic candidates","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}